HighCape Capital is a growth equity fund created in 2013 by a group of highly experienced executives for the sole purpose of helping innovative Life Sciences companies transition from the initial stages of their business cycle into successful, thriving organizations. Our team members have backgrounds in founding, financing, leading, growing and exiting a variety of Life Sciences companies across multiple industry segments.
We embrace the excitement of entrepreneurship along with the attendant challenges and emotions. It is rare to find a team of investors who can say “we have sat in your seat”, but our team really has. We approach each potential partnership with the idea that combining the right capital, leadership and strategic plan is the best way to optimize the opportunity.
Where We Invest
We are a multidisciplinary team of industry veterans that brings a breadth of investment and operating experience and expertise to commercial-stage life sciences companies.
The HighCape team have been amazing partners in reimagining Wellinks. They approach ‘adding value’ as a responsibility, not a buzz phrase. Theirs is an energetic, thoughtful, and accomplished team that has helped us see around corners while always remaining solidly in ours. I can’t recommend HighCape enthusiastically enough.
HighCape Capital was very supportive of our employees and management team. While we only had one representative from HighCape on our board, I was impressed how all of their partners contributed at different times to the success of the company. I found them to be fair, honest, and a great team to work with.
From the start, HighCape was a great partner for Quantum-Si during the SPAC transaction. The level of experience and sophistication conducting the process was a tremendous asset to the success of the effort. The HighCape team contributed across many fronts adding value in finance, recruiting, marketing and legacy relationships with investors.
Committed to the development of digital care for COPD and other respiratory diseases.
Quantum-Si is leading the transition from analog to digital proteomics thus enabling a new generation of more sensitive and accurate research tools and diagnostics.
Aziyo Biologics (Nasdaq: AZYO) is a commercially oriented biotechnology company focused on regenerative medicine in the areas of cardiology, orthopedics and wound care.
Cheetah Medical was the first to offer a fully non-invasive and precise approach to fluid management.